Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Buck Stops With Kraemer: Baxter CEO Resigns To Restore Investor Confidence

This article was originally published in The Gray Sheet

Executive Summary

A fresh round of restructuring will save Baxter $200 mil.-$300 mil. a year, shore up core business segments and help pave the way for future growth, the firm says
Advertisement

Related Content

People In Brief
People In Brief
“Realistic” CEO Parkinson Will Lead Baxter Through Continued Restructuring
“Realistic” CEO Parkinson Will Lead Baxter Through Continued Restructuring
Baxter bids general counsel adieu
Baxter bids general counsel adieu
Cerus Pathogen Inactivation Trial Delay Alters Landscape For Vitex, Navigant
Baxter Profit Pressures Lead To Expanded Restructuring, SEC Probe
Baxter Profit Pressures Lead To Expanded Restructuring, SEC Probe
Advertisement
UsernamePublicRestriction

Register

MT019665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel